FDA approves Odactra for treating pediatric house dust mite-induced allergic rhinitisJanuary 26th 2023
Odactra (House Dust Mite Allergen Extract; ALK) has received approval from the US Food and Drug Administration for use in patients aged 12 to 17 years with house dust mite-induced allergic rhinitis.
The value of early diagnosis of autism spectrum disorderJanuary 20th 2023
Colleen Kraft, MD, senior medical director of clinical adoption at Cognoa, discusses how autism spectrum disorder (ASD) development affects children and families, along with how early diagnosis and treatment can improve the lives of children with ASD.
Bivalent COVID-19 booster safety profile consistent with monovalent vaccineJanuary 17th 2023
The Centers for Disease Control and Prevention has provided an updated safety profile on the bivalent COVID-19 booster vaccine in children aged 5 to 11 years, showing similar adverse events to the monovalent vaccine.